Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders

Pharmaceutics. 2023 Jan 6;15(1):204. doi: 10.3390/pharmaceutics15010204.

Abstract

Cannabinoids have a major therapeutic value in a variety of disorders. The concepts of cannabinoids are difficult to develop, but they can be used and are advantageous for a number of diseases that are not sufficiently managed by existing treatments. Nanoconjugation and encapsulation techniques have been shown to be effective in improving the delivery and the therapeutic effectiveness of drugs that are poorly soluble in water. Because the bioavailability of cannabinoids is low, the challenge is to explore different administration methods to improve their effectiveness. Because cannabinoids cross the blood-brain-barrier (BBB), they modify the negative effects of inflammatory processes on the BBB and may be a key factor in the improvement of BBB function after ischemic disease or other conditions. This review discusses various types of cannabinoid administration, as well as nanotechnologies used to improve the bioavailability of these compounds in CNS diseases.

Keywords: CBD; THC; brain; cannabinoids; endocannabinoid system; lipids; nanoparticles; neurodegenerative diseases; targeted delivery.

Publication types

  • Review